The kidneys hold tiny filters called glomeruli that remove waste and extra water into the urine, and the eGFR estimates how much blood they filter each minute.1 Doctors often check it at routine checkups, from the creatinine measured in a basic metabolic panel.1 It matters for GLP-1 medicines in two ways: semaglutide slowed its decline in a large kidney trial, and dehydration from side effects can push it down.2,3
How it is estimated
Measuring the filtering rate directly means injecting a substance and timing how fast the kidneys clear it. That test is complicated and not widely available, so it is kept for cases such as extreme obesity or kidney donation. The usual estimate starts from creatinine, a waste product of normal muscle wear and tear that builds up in the blood when the kidneys work poorly. Because people make different amounts of creatinine depending on their size, diet and activity, a formula adds age, weight, height and sex. Some labs use cystatin C, a protein whose level is not affected by muscle size, age or diet, alone or together with creatinine. MedlinePlus lists cases where cystatin C may be used instead: people younger than 18 or older than 65, people with a lot of muscle mass, people with obesity, and pregnancy.1
What the numbers mean
- 90 to 100: probably no kidney disease.
- 60 to 90: may be early-stage kidney disease.
- 15 to 60: may be kidney disease.
- Below 15: may be kidney failure.
MedlinePlus stresses that these are general ranges: eGFR varies with age, body size and other conditions, is not a perfect test, and can be abnormal without kidney damage. A result below what is normal for the person is usually followed by other tests. Albumin in the urine may be one of the first signs of kidney disease, so the tests include protein in the urine, a urine albumin-to-creatinine ratio, blood urea nitrogen, or an ultrasound or CT scan of the kidneys.1
Who is tested, and the symptoms
Early kidney disease usually causes no symptoms, which is why the number is checked in people at higher risk. MedlinePlus names diabetes, high blood pressure, heart disease, obesity, smoking, age over 60, and a family history of kidney disease, diabetes or high blood pressure. Later kidney disease can bring swelling of the legs, feet, ankles, hands or face; urinating more or less often than usual; dry or itchy skin; fatigue; muscle cramps; nausea and vomiting; and loss of appetite.1
What semaglutide did to eGFR in FLOW
The FLOW trial tested semaglutide 1 mg in adults with type 2 diabetes and chronic kidney disease. Its main outcome counted kidney failure, defined as dialysis, a transplant or an eGFR below 15, a drop in eGFR of at least 50%, and death from kidney or cardiovascular causes. That outcome was 24% less frequent on semaglutide, a hazard ratio of 0.76. The yearly fall in eGFR was also slower, by 1.16 milliliters per minute per 1.73 m² of body surface.2 On the basis of FLOW, the Ozempic label added the use of reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.4
When eGFR can fall on a GLP-1
The Wegovy label reports acute kidney injury after approval, in some cases needing hemodialysis. Most of these cases happened in people whose nausea, vomiting or diarrhea led to dehydration. The label asks doctors to monitor kidney function in patients with side effects that could lead to fluid loss.3
Sources
- MedlinePlus. Glomerular filtration rate (GFR) test. National Library of Medicine; last updated September 30, 2026, read November 20, 2026. medlineplus.gov
- Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med 2024;391:109-121. Funded by Novo Nordisk; NCT03819153. doi:10.1056/NEJMoa2403347
- WEGOVY (semaglutide) injection prescribing information. Novo Nordisk; DailyMed, version 19, published June 30, 2026; section 5.5. dailymed.nlm.nih.gov
- OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 1, 5.6 and 14.3. accessdata.fda.gov
Related analyses
Ozempic side effects: how common each one is by dose, and when they ease
Ozempic dosing schedule: 0.25 mg to 2 mg, week by week, with your own dates
Wegovy side effects: how common each one is, when it peaks and how long it lasts
Ozempic vs Wegovy: the same drug under two labels, compared by dose, results and price
Log each eGFR and creatinine result with the date, so you and your doctor can see the trend.
Open Dose Insider